This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Predictors for partial suppression of spermatogenesis of
hormonal male contraception
Jing-Wen Li1,2, Yi-Qun Gu2
Peking Union Medical College Postgraduate School, Beijing 100730, China
2National Research Institute for Family Planning, Beijing 100081, China
Abstract
Aim: To analyze factors influencing the efficacy of hormonal suppression of spermatogenesis for male contraception.
Methods: A nested case-control study was conducted, involving 43 subjects, who did not achieve azoospermia or
severe oligozoospermia when given monthly injections of 500 mg testosterone undecanoate (TU), defined as partial
suppressors compared with 855 subjects who had suppressed spermatogenesis (complete suppressors). Sperm
density, serum testosterone, luteinizing hormone (LH) and follicle stimulating hormone (FSH) concentrations at the
baseline and the suppression phase were compared between partial and complete suppressors. Polymorphisms of
androgen receptor (AR) and three single nucleotide variants and their haplotypes of FSH receptor (FSHR) genes
determined by polymerase chain reaction (PCR) and DNA sequencing technique were compared between 29 partial
and 34 complete suppressors. Results: Baseline serum LH level was higher and serum LH as well as FSH level during
the suppression phase was less suppressed in partial suppressors. Additionally, in a logistic regression analysis larger
testis volume, higher serum FSH concentrations alone, or interaction of serum LH, FSH, testosterone and sperm
concentrations were associated with degree of suppression. The distribution of polymorphisms of AR or FSH
receptor genes did not differ between partial and complete suppressors. In cases with incomplete FSH suppression
(FSH > 0.2 IU/L), the chances of reaching azoospermia were
1.5 times higher in the subjects with more than 22 CAG
triplet repeats. Conclusion: Partial
suppression of spermatogenesis induced by 500 mg TU monthly injections is
weakly influenced by hormonal and clinical features but not polymorphism in AR and FSHR
genes. (Asian J Androl 2008 Sep; 10: 723_730)
Keywords: male contraception; genetic polymorphism; androgen receptor; CAG repeats;
follicle stimulating hormone receptor; single nucleotide polymorphism; sperm concentration
Correspondence to: Prof. Yi-Qun Gu, Department of Male Clinic Research, National Research Institute for Family Planning, Beijing
100081, China.
Tel/Fax: +86-10-6214-8629
E-mail: ygu90@hotmail.com
Received 2008-02-26 Accepted 2008-06-10
DOI: 10.1111/j.1745-7262.2008.00432.x
1 Introduction
The goal of hormonal male contraception is induction
of azoospermia or severe oligozoospermia to the levels
required for reliable prevention of pregnancy [1_3].
However, the heterogeneity response of subjects to
hormonal suppression of spermatogenesis remains an
unresolved problem. Despite marked and sustained
suppression of serum gonadotrophins, suppression of
spermatogenesis is incomplete in a minority of subjects in most
studies. Such variability in response is significant
between and within ethnic groups [4, 5], and is a key issue
influencing clinical efficacy, general acceptability and
wider applicability of hormonal male contraceptives.
While seeking an explanation for the variability in
response, previous studies have revealed differences in
pretreatment hormone values [6, 7], intratesticular
testosterone (T) metabolism [8] and in the sensitivity of the
pituitary-hypothalamic feedback system to exogenous T
[9, 10]. In recent years an increasing body of evidence
has shown that individual response to drug therapy at the
molecular level is in part determined by genetic
polymorphism, resulting in subtle differences in protein action or
drug metabolism [11].
Based on previous findings, the potential factors that
might influence the efficacy of hormonal male
contraception, including clinical parameters, hormone values and
genetic polymorphism in androgen receptor (AR) and
follicle stimulating hormone receptor (FSHR), were
measured and assessed in the present nested case-control
study to identify predictors of partial (or incomplete)
suppression of spermatogenesis with hormonal male contraception.
2 Materials and methods
2.1 Clinical protocol
The contraceptive efficacy study was an open-label,
multicenter, phase III clinical trial with World Health
Organization (WHO) standard monitoring, and consisted
of a 2-month baseline period prior to a 30-month
treatment period and a 12-month recovery period. The study
enrolled 1 045 healthy fertile Chinese men, aged
20_45 years, from 10 family planning service centers
throughout China. After screening of participants and their
partners for eligibility, subjects entered the treatment period
and received monthly injections of testosterone undeconate (TU) in 500 mg doses for up to 6 months
(suppression phase) followed by a 24-month efficacy
phase. Injections were administered and recorded by
research nurses at each center. Injections outside a time
window of 2 days were considered missed. During the
suppression phase 190 subjects discontinued the trial,
including 43 subjects who failed to reach azoospermia
or severe oligozoospermia (¡Ü
1 × 106/mL) and were defined as partial suppressors, while 855 subjects who had
suppressed spermatogenesis
(¡Ü 1 × 106/mL) were defined
as complete suppressors and met entry criteria of the
efficacy phase. During the efficacy phase no other form of
contraception except monthly injections of TU at doses
of 500 mg were allowed and subjects underwent general
physical and andrological examination, provided semen
and fasting blood samples at 3 monthly intervals before
each TU injection for reproductive hormones and
biochemistry assays. During the recovery period, subjects
were also asked to attend the clinic for physical
examinations and to provide semen and fasting blood samples
at 3 monthly intervals for 12 months. Couples were
advised to use a reliable contraceptive method if they wanted
to avoid pregnancy.
Written informed consent was obtained from the
participants and their partners at entry into the trial. The
study and consent form were approved by the Ethics
Committee and Institutional Review Board of each
participating center as well as the Scientific and Ethical Review
Group of the WHO Human Reproduction Programme.
2.2 Subjects received assay of genetic polymorphisms
The assay for genetic polymorphisms was a nested
case-control study. A total of 63 subjects, including 29
partial and 34 complete suppressors who matched
partial suppressors in clinical features, provided blood
samples for polymorphic assay of AR and FSHR genes
after informed consent and were allocated to the test and
the control group, respectively.
2.3 Measurements
Semen analyses were performed according to the WHO laboratory manual [12]. Azoospermia was defined
as absence of sperm from seminal fluid smear after
centrifugation at 3 000 × g for 15 min. Severe
oligozoospermia was defined as sperm concentrations of
1 × 106/mL or less. Testis volume was estimated using Prader's
orchidometer with measurements combined to calculate
the total testis volume. Serum samples were measured
together in batches in the central laboratory of the Beijing
Coordinating Center. Serum T, luteinizing hormon (LH)
and follicle stimulating hormone (FSH) were assayed using
commercial kits supplied by Immunometrics (London, UK)
[5]. The assay sensitivities were 0.35 nmol/L,
0.1 IU/L and 0.2 IU/L for T, LH and FSH, respectively. The mean
intra-assay coefficients of variation for serum T, LH and
FSH were 7.1%, 3.4% and 3.2%, respectively. The mean
inter-assay coefficient of variation for serum T, LH and
FSH were 15.4%, 7.5% and 7.8%, respectively.
2.4 DNA isolation and polymorphic analysis
Genomic DNA was isolated from peripheral blood samples using kits according to the manufacturer's
instructions. The number of CAG triplet repeats in AR
and the single nucleotide polymorphism (SNP) in FSHR
genes were determined by polymerase chain reaction
(PCR) and using a DNA sequencing technique following
previous research [13_16].
2.5 Statistics
Statistical analyses were performed using SPSS
software package for windows (version 13.0; SPSS, Chicago,
IL, USA). All parameters in the present study were tested
for normal distribution. Sperm concentration, serum LH
and FSH data that were not normally distributed were
logarithm-transformed before analysis. Logistic
regression modeling with backward stepwise (likelihood ratio)
criterion was used to assess the variables affecting the
suppression of spermatogenesis. Independent samples
t-test and one-way analysis of variance
(ANOVA) were used to compare differences after logarithm
transformation. The χ2-test was used to compare frequencies.
Descriptive statistics were given as either mean ± SEM/SD
or median together with minimum and maximum.
All hypothesis tests were two-tailed.
P < 0.05 was considered significant.
3 Results
3.1 Analyses of clinical parameters, sperm density and
hormone values
Baseline serum LH was significantly higher among
partial suppressors, whereas there was no significant
difference at the baseline of age, body mass index (BMI),
total testis volume, sperm density, serum T and FSH
levels between partial and complete suppressors. During the
suppression phase, serum LH and FSH levels were
significantly less suppressed in partial compared with
complete suppressors (Table 1).
Logistic regression analysis showed that larger
testis volume (P = 0.002, Expβ = 0.82), higher serum FSH
concentrations either at the baseline
(P = 0.032, Expβ = 0.47)
or at the suppression phase (P = 0.002,
Expβ = 0.000) alone, or interaction of serum LH concentrations at the
baseline by BMI (P = 0.022, Expβ = 0.99), serum T
concentrations at the baseline by sperm concentrations
at the baseline (P = 0.014, Expβ = 0.99), and serum
FSH concentrations at the baseline by serum FSH
concentrations at the suppression phase
(P = 0.019, Expβ = 1.15) were associated with greater risk of
partial suppression of spermatogenesis.
3.2 The number of CAG triplet repeats within exon 1 in
androgen receptor gene
The distribution of CAG triplet repeat lengths was
virtually identical in partial and complete suppressors
(Figure 1), with no significant difference in the mean
repeat length between the test group
(23.6 ± 3.6, range:18_32) and the control group (23.0 ± 2.4, range:
19_32). However, subjects with CAG triplet repeats
numbering more than 22 had a chance of achieving azoospermia
1.5 times higher than that in cases with incomplete FSH
suppression (FSH > 0.2 IU/L).
3.3 Single nucleotide polymorphisms (SNPs) of FSHR
at nucleotide position _29 (FSHR promoter), amino acid
position 307 and 680 (exon 10)
The distribution of FSHR genotype at nucleotide
position _29, amino acid position 307 and 680 in both the
test group and the control group is summarized in Table 2.
There was no significant difference in the frequency of
distribution among the genotype
(P > 0.05,
χ2-test). The serum FSH concentrations at the baseline among FSHR
genotypes are shown in Table 3. No significant
difference in serum FSH concentrations at the baseline among the
FSHR genotypes either in the test group or the control
group was noted (P > 0.05, ANOVA).
3.4 FSHR haplotypes
The overall frequency of four FSHR haplotypes in
the two groups is listed in Table 4. No significant
difference in frequency of distribution between the two
groups was found (P > 0.05,
χ2-test). These four haplotypes accounted
for 77.8% of the FSHR alleles of the two groups and combined into the 10 major
combinations shown in Tables 5 and 6, in which only nine
groups were presented because two possible allelic
combinations in group 5 (double heterozygous) could not be
distinguished and considered together. The distribution
of genotype between the test and the control group was
not significantly different (P > 0.05,
χ2-test). No significant difference in the FSH levels at the baseline among
the FSHR genotype either in the test group or in the
control group was found (Tables 5 and 6). In addition, a
correlation between genotypes and FSH concentrations
at the baseline was not found in the present study either.
4 Discussion
In this study, we used 500 mg TU monthly injections
alone in over 1 000 healthy fertile Chinese men. Among
these, 43 subjects remained partial suppressors in failing
to achieve either azoospermia or severe oligozoospermia
within a 6-month suppression phase comprising a 4.7%
rate of only partial suppression by cumulative life-table
analysis (data not shown). This finding is consistent with
that described in the phase II study of the same regimen
[5] and other studies [4]. However, the reason for
incomplete suppression of spermatogenesis within and
between populations is not yet understood. Incomplete
gonadotrophin suppression due to variations of
pharmacogenetics is one plausible explanation [17]. In the
present study, higher baseline serum LH and serum LH
and FSH during the suppression phase in partial
suppressors were significant predictors of incomplete
suppression of spermatogenesis. Furthermore, clinical features,
such as total testis volume and BMI either alone or
through interactions with circulating LH or FSH, were
associated with incomplete spermatogenic suppression.
It has been reported that genetic polymorphism has
an influence on pharmacological activity [18]. However,
in the present study, DNA from the test group of partial
suppressors and the control group of complete
suppressors was analyzed to determine the polymorphisms of
the CAG triplet repeat in AR gene and three different
SNP in FSHR gene were found not to have any
relationship to suppressor status.
Androgens exert their effects through AR, a
DNA-binding transcription factor protein, encoded by a
single-copy gene, and the polymorphic CAG triplet repeat is
contained in exon 1 of AR gene. This polymorphism has
been reported to influence sperm output most probably
as a result of higher transactivational activity of AR [19],
and a negative correlation has been reported between
number of CAG triplet repeats and sperm concentration
but not testicular size in normal men [20].
However, the mean length of CAG triplet repeats in the two groups of
this study was 22, consistent with previous research in
the Chinese male population [21], without any
significant difference between the test group of partial
suppressors and the control group of complete suppressors. The
present finding is also consistent with another study
using androgen alone [22], indicating that partial
suppression of spermatogenesis is not directly related to
polymorphism of AR gene in androgen alone studies.
However, another post-hoc analysis of a mixed
population treated with different regimens of hormonal male
contraception has reported that azoospermia was more
frequent in some treatments according to CAG triplet
repeats [23]. In the present study, however, there was
no significant relationship between the number of CAG
triplet repeats and achievement of azoospermia, possibly
due to lower power. Odds ratios (OR) obtained in the
present study demonstrated that subjects with CAG
triplet repeats numbering more than 22 had a chance of
achieving azoospermia 1.5 times higher than that in cases
with incomplete FSH suppression (> 0.2 IU/L). This
reveals that the influence of polymorphism in AR gene
on hormonal male contraception might be exerted when
combined with other factors, such as suppression
degree of serum gonadotrophins.
The key role for serum FSH in Sertoli cell and
spermatogonial development has been established in all
species. In monkeys, serum FSH levels are correlated
with spermatogonial development and inadequate suppression of serum FSH is a potential reason for
contraceptive failure [24]. FSH stimulates spermatogenesis
using a specific receptor (FSHR) that is a member of the
G protein-coupled receptor family. Mutation screening
of the FSHR gene reveals various SNP, both in the core
promoter and in the coding region. In particular, a
common SNP in the core promoter of human FSHR gene at
nucleotide position _29 has been reported. In exon 10,
two SNP are also discovered at nucleotide position 919
and 2039 (numbered according to the translation start
codon with ATG as "1") corresponding to amino acid
positions 307 and 680 of the mature protein.
Polymorphism within exon 10 results in two major, almost equally
common allelic variants in the Caucasian population:
Thr307-Asn680 and
Ala307-Ser680 [25]. Investigations into
the distribution of these two variants are controversial.
The distribution of allelic variants was not different
between normal and infertile men and women [26, 27],
whereas significant difference was found between
patients and controls [15, 28], suggesting that ethnic and
gender differences could be involved and that the
polymorphism might affect human reproductive function
indirectly.
In the present study, the SNP at position _29 and in
exon 10 in the two groups was analyzed. The prevalence of polymorphisms
in this study was similar to that reported by others [29]. The haplotypes determined by
the three SNPs of the FSHR gene were analyzed and restriction fragment length polymorphism analysis has
confirmed complete linkage between the two allelic
variants at positions 307 and 680. Considering the
polymorphism in the promoter as well, four most common
haplotypes result from the three SNPs of FSHR gene:
A-29-A919-A2039 (A-Thr-Asn),
G-29-A919-A2039 (G-Thr-Asn),
A-29-G919-G2039 (A-Ala-Ser) and
G-29-G919-G2039
(G-Ala-Ser) [14]. These four haplotypes accounted for 77.8%
of FSHR alleles of the two groups, whereas in
Caucasian population they account for over 99% [30],
indicating an ethnic difference. Nevertheless, unlike in other
research in women [31], in the present study, these
polymorphisms did not determine likelihood of partial or
complete suppression of spermatogenesis nor was there any
relationship found between FSHR polymorphisms and basal FSH levels.
In conclusion, partial or incomplete suppression of
spermatogenesis status induced by 500 mg TU monthly
injections is attributable to both hormonal and clinical
factors, whereas polymorphisms in AR and FSHR genes
seem to have no direct influence. The relationship
between genetic polymorphism and partial suppression of
spermatogenesis requires more extensive testing with
larger sample sizes.
Acknowledgment
This work was sponsored by the World Health Organization (WHO, Project A05233). We gratefully
acknowledge the help of Mr Jing Dong and Mr Heng Zhao
with performing the statistical data analysis. We thank
Dr He-Ming Yu and Ms Jin-Song Huang for training of
molecular biological technique. We also thank
Professors David Handelsman and Christina Wang for
reviewing and commenting on the paper.
References
1 World Health Organization Task Force on Methods for the
Regulation of Male Fertility. Contraceptive Efficacy of
Testosterone-Induced Azoospermia and Oligozoospermia in
Normal Men. Fertil Steril 1996; 65: 821_9.
2 Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M,
Jockenhel F, et al. More than eight years' hands-on experience
with the novel long-acting parenteral testosterone undecanoate.
Asian J Androl 2007; 9: 291_7.
3 Liu ST, Gui YL, Lin CH, He CH. Hormonal contraception in
Chinese men: variations in suppression of spermatogenesis
with injectable testosterone undecanoate and levonorgestrel
implants. Asian J Androl 2004; 6: 41_6.
4 Rates of testosterone-induced suppression to severe
oligozoospermia or azoospermia in two multinational clinical
studies. World Health Organization Task Force on Methods
for the Regulations of Male Fertility. Int J Androl 1995; 18:
157_65.
5 Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK,
et al. A multicenter contraceptive efficacy study of injectable
testosterone undecanoate in healthy Chinese men. J Clin
Endocrinol Metab 2003; 88: 562_8.
6 Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag
E. Potential of testosterone buciclate for male contraception:
endocrine differences between responders and non-responders.
J Clin Endocrinol Metab 1995; 80: 2394_403.
7 Handelsman DJ, Farley TM, Peregoudov A, Waites GM. Factors
in nonuniform induction of azoospermia by testosterone
enanthate in normal men. World Health Organazation
Task Force on Methods for the Regulation of Male Fertility. Fertil
Steril 1995; 63: 125_33.
8 Anderson RA, Kelly RW, Wu FC. Comparison between
testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study.
V. Localization of higher 5 alpha-reductase activity to the reproductive tract
in oligozoospermic men administered supraphysiological doses
of testosterone. J Androl 1997; 18: 366_71.
9 Buchter D, von Eckardstein S, von Eckardstein A, Kamischke
A, Simoni M, Behre HM, et al. Clinical trial of transdermal
testosterone and oral levonorgestrel for male contraception. J
Clin Endocrinol Metab 1999; 84: 1244_9.
10 Kamischke A, Ploger D, Venherm S, von Eckardstein S, von
Eckardstein A, Nieschlag E. Intramuscular testosterone
undecanoate with or without oral levonorgestrel: a randomized
placebo-controlled feasibility study for male contraception.
Clin Endocrinol (Oxf) 2000; 53: 43_52.
11 Evans WE, Relling MV. Pharmacogenomics: translating
functional genomics into rational therapeutics. Science 1999;
286: 487_91.
12 World Health Organization. WHO laboratory manual for the
examination of human semen and sperm-cervical mucus
interaction, 4th ed. Cambridge: Cambridge University Press.
1999; p4_26.
13 Wallerand H, Remy-Martin A, Chabannes E, Bermont L, Adessi
GL, Bittard H. Relationship between expansion of the CAG
repeat in exon 1 of the androgen receptor gene and idiopathic
male infertility. Fertil Steril 2001; 76: 769_74.
14 Pengo M, Ferlin A, Arredi B, Ganz F, Selice R, Garolla A,
et al. FSH receptor gene polymorphisms in fertile and infertile Italian
men. Reprod Biomed Online 2006; 13: 795_800.
15 Sudo S, Kudo M, Wada S, Sato O, Hsueh AJ, Fujimoto S.
Genetic and functional analysis of polymorphisms in the human
FSH receptor gene. Mol Hum Reprod 2002; 8: 893_9.
16 Daelemans C, Smits G, de Maertelaer V, Costagliola S, Englert
Y, Vassart G, et al. Prediction of severity of symptoms in
iatrogenic ovarian hyperstimulation syndrome by
follicle-stimulating hormone receptor Ser680Asn polymorphism. J
Clin Endocrinol Metab 2004; 89: 6310_15.
17 McLachlan RI, Robertson DM, Pruysers E, Ugoni A,
Matsumoto AM, Anawalt BD, et al. Relationship between
serum gonadotropins and spermatogenic suppression in men
undergoing steroidal contraceptive treatment. J Clin Endocrinol
Metab 2004; 89:142_9.
18 Beaune PH. Pharmacogenetics: from basic research to clinical
applications. Ann Pharm Fr 2007; 65: 365_70.
19 Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O,
Naruse S, et al. Expanded polyglutamine stretches interact with
TAFII130, interfering with CREB-dependent transcription. Nat
Genet 2000; 26: 29_36.
20 von Eckardstein S, Syska A, Gromoll J, Kamischke A, Simoni
M, Nieschlag E. Inverse correlation between sperm
concentration and number of androgen receptor CAG repeats
in normal men. J Clin Endocrinol Metab 2001; 86: 2585_90.
21 Wang G, Chen G, Wang X, Zhong J, Lu J. The polymorphism
of (CAG)n repeats within androgen receptor gene among
Chinese male population. Zhonghua Yi Xue Yi Chuan Xue
Za Zhi (in Chinese) 2001; 18: 456_8.
22 Yu B, Handelsman DJ. Pharmacogenetic polymorphisms of
the AR and metabolism and susceptibility to hormone-induced
azoospermia. J Clin Endocrinol Metab 2001; 86:
4406_11.
23 Eckardstein SV, Schmidt A, Kamischke A, Simoni M, Gromoll
J, Nieschlag E. CAG repeat length in the androgen receptor
gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol
(Oxf) 2002; 57: 647_55.
24 Narula A, Gu YQ, O'Donnell L, Stanton PG, Roberson DM,
McLachlan RI, et al. Variability in sperm suppression during
testosterone administration to adult monkeys is related to
follicle stimulating hormone suppression and not to
intratesticular androgens. J Clin Endocrinol Metab 2002; 87:
3399_406.
25 Simoni M, Nieschlag E, Gromoll J. Isoforms and single
nucleotide polymorphisms of the FSH receptor gene:
implications for human reproduction. Hum Reprod Update
2002; 8: 413_21.
26 Conway GS, Conway E, Walker C, Hoppner W, Gromoll J, Simoni
M. Mutation screening and isoform prevalence of the follicle
stimulating hormone receptor gene in women with premature ovarian
failure, resistant ovary syndrome and polycystic ovary syndrome.
Clin Endocrinol (Oxf) 1999; 51: 97_9.
27 Simoni M, Gromoll J, Hoppner W, Kamischke A, Krafft T,
Stahle D, et al. Mutational analysis of the follicle-stimulating
hormone (FSH) receptor in normal and infertile men:
identification and characterization of two discrete FSH receptor
isoforms. J Clin Endocrinol Metab 1999; 84: 751_5.
28 Laven JS, Mulders AG, Suryandari DA, Gromoll J, Nieschlag
E, Fauser BC, et al. Follicle-stimulating hormone receptor
polymorphisms in women with normogonadotropic anovulatory infertility. Fertil Steril 2003; 80: 986_92.
29 Asatiani K, Gromoll J, Eckardstein SV, Zitzmann M, Nieschlag
E, Simoni M. Distribution and function of FSH receptor
genetic variants in normal men. Andrologia 2002; 34: 172_6.
30 Ahda Y, Gromoll J, Wunsch A, Asatiani K, Zitzmann M,
Nieschlag E, et al. Follicle-stimulating hormone receptor gene
haplotype distribution in normozoospermic and azoospermic
men. J Androl 2005; 26: 494_9.
31 de Koning CH, Benjamins T, Harms P, Homburg R, van
Montfrans JM, Gromoll J, et al. The distribution of FSH
receptor isoforms is related to basal FSH levels in subfertile
women with normal menstrual cycles. Hum Reprod 2006;
21: 443_6.
|